Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

CAMBRIDGE, Mass., May 24, 2023 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating¬†precisely¬†targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the TD Cowen 4th Annual Oncology Innovation … Read more